Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiochemotherapy with or without durvalumab for locally advanced anal squamous cell carcinoma
2018-003005-25Phase 2Active
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Sep 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, fluorouracil and mitomycin c in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Disease-free survival and 3-year disease-free survival rate. Started Sep 2019; status: active.
02
Drugs
durvalumabfluorouracilmitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2018-003005-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003005-25.